COVID-19 Research Paper Volume 14, Issue 1 pp 73—108
Decreased TMPRSS2 expression by SARS-CoV-2 predicts the poor prognosis of lung cancer patients through metabolic pathways and immune infiltration
Figure 1. TMPRSS2 expression in lung cancer. (A) The mRNA expression of TMPRSS2 in different cancers from the TIMER database. (B) Upregulated or downregulated expression of TMPRSS2 in various tumors compared with normal tissues in the Oncomine database. (C) Box plots showing TMPRSS2 mRNA level in different types of lung cancer patients and normal individuals from the Oncomine database. (D) TMPRSS2 mRNA level in lung cancer patients and normal individuals in the GSE10072 (normal, n = 49; lung cancer, n = 58), GSE33532 (normal, n = 20; lung cancer, n = 80), GSE30219 (normal, n = 14; lung cancer, n = 293) and GSE21933 (normal, n = 21; lung cancer, n = 81) datasets. (E) TMPRSS2 expression is decreased in lung cancer (n = 81) compared with noncancerous adjacent tissues (n = 81) from the TCGA database. (F) TMPRSS2 expression in 58 and 50 matched LUAD and LUSC samples and adjacent normal lung tissues in the TCGA database was determined. *p < 0.05, **p < 0.01, ***p < 0.001.